| | Nucleoside-sparing regimens |
 | | The increasing link between nucleoside analogues and lipoatrophy and increased potency of ritonavir-boosted protease inhibitors have led to a number of so-called nucleoside sparing strategies, both in treatment naïve and experienced patients. |
 | | The results are remarkable, and compartmental penetration is considered within the study, but a patient advantage apart from reduced drug use is not clear, as tolerability of boosted PI regimens is largely related to the boosted-PI component of the therapy. |
 | | At baseline nucleosides were stopped and patients monitored at week two and then monthly for viral load (LQ=20 copies/ml), CD4, and activation markers (CD38 and HLA-DR), and at baseline and week 48 with DEXA. |
| www.i-base.org.uk /pub/htb/v4/htb4-7/Nucleoside.html (1755 words) |